An
interleukin (IL)-4-containing
tumor environment is reported to be beneficial for immune clearance of
tumor cells in vivo; however, the effect of
IL-4 on the effector CD8+ T cells contributing to
tumor clearance is not well defined. We have used the immunogenic HLA-CW3-expressing P815 (P.CW3)
mastocytoma and investigated whether
IL-4 expression by the
tumor affects
tumor clearance and, if so, whether it alters the
tumor-induced Vbeta10+ CD8+ T-cell response. P.CW3 were stably transfected with
IL-4 or the empty control vector, and independent cell lines were injected i.p. into syngeneic DBA/2 mice. After apparent clearance of primary
tumors over 12 to 15 days, secondary
tumors arose that lacked surface expression and H-2-restricted antigen presentation of CW3 in part due to the loss of the
HLA-CW3 expression cassette. Surprisingly, mice that received IL-4-producing
tumor cells showed delayed primary
tumor clearance and were significantly more prone to develop secondary
tumors compared with mice receiving control
tumor cells.
Tumor clearance was dependent on CD8+ T cells. The IL-4-secreting P.CW3
tumor cells led to markedly higher
mRNA expression of
IL-4 and
granzyme A and B but no differences in IFN-gamma and
IL-2 production, cell proliferation, or ex vivo CTL activity in primary Vbeta10+ CD8+ T cells when compared with the control
tumor cells. We concluded that
tumor-derived
IL-4 selectively changed the quality of the
tumor-induced CD8+ T-cell response and resulted in unexpected negative effects on
tumor clearance. These data bring into question the delivery of
IL-4 to the
tumor environment for improving
tumor immunotherapy.